This section aims to outline the clinical implications of these opposing forces in the context of HNSCC, setting the stage for a discussion of how utilizing the balance between pro-angiogenic and anti-angiogenic VEGF variants may provide new avenues for targeted therapies. This evidence concerns the gene VEGFA and head and neck squamous cell carcinoma.